Raymond James Financial Inc. Invests $5.12 Million in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Raymond James Financial Inc. bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 15,581 shares of the medical research company's stock, valued at approximately $5,119,000. Raymond James Financial Inc. owned approximately 0.06% of Bio-Rad Laboratories at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BIO. Metis Global Partners LLC increased its stake in Bio-Rad Laboratories by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock worth $234,000 after purchasing an additional 30 shares in the last quarter. UMB Bank n.a. boosted its holdings in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after buying an additional 32 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after acquiring an additional 34 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of Bio-Rad Laboratories by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company's stock valued at $234,000 after acquiring an additional 34 shares during the period. Finally, Ballentine Partners LLC lifted its position in shares of Bio-Rad Laboratories by 5.2% in the 4th quarter. Ballentine Partners LLC now owns 714 shares of the medical research company's stock valued at $235,000 after acquiring an additional 35 shares in the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Bio-Rad Laboratories Stock Down 1.5 %

Shares of NYSE BIO traded down $3.83 during mid-day trading on Friday, reaching $243.33. The company had a trading volume of 328,120 shares, compared to its average volume of 290,283. The stock has a market capitalization of $6.82 billion, a PE ratio of -3.74 and a beta of 0.98. Bio-Rad Laboratories, Inc. has a twelve month low of $241.87 and a twelve month high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock's 50 day moving average is $293.54 and its 200-day moving average is $322.48.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BIO. Royal Bank of Canada reissued an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Finally, Wells Fargo & Company decreased their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has an average rating of "Moderate Buy" and an average target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.